TTP Labtech Revenues up 43%
News Jun 23, 2014
Most of this growth is based on the strength of TTP Labtech’s core products in the areas of cell imaging, liquid handling and sample management. In particular mirrorball® and comPOUND® saw an accelerated growth of over 300%.
“We have a team of passionate, talented and dedicated individuals behind each product and a collaborative relationship with our customers – something that differentiates us from other technology-based companies”, remarked Dr Jas Sanghera, managing director at TTP Labtech.
A focus on global distribution has led to 24% of product sales outside of the US and Europe, with a significant proportion of this in Asia. TTP Labtech is now in a strong position to continue growing the business. Dr Sanghera’s strategy to maintain the focus on product quality, even in a challenging economic environment, has proved to be successful.
Continued success also requires maintaining an innovative culture and a willingness to adapt to market changes. The current trend in assay development is a move towards greater levels of both accuracy and precision, while making use of smaller volumes at an increased throughput – a challenge which can only be assured by automated instrumentation. Many of TTP Labtech’s products, in particular the mosquito range, are well positioned to rise to this challenge and provide real value to customers in that field.
Dr Sanghera continued, “We predict strong growth for the next year from our most recently launched products (dragonfly® and arktic®). In addition we have opened a new online store for consumables that we expect will make a significant contribution to the revenue next year. Innovation, which is so important for the company, is driven by our strong focus on our customers and we will continue to develop these relationships in the future”.
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
Potential Barcode Identified for a Form of Alcoholic Liver DiseaseNews
NIAAA-supported researchers have discovered that extracellular vesicles released by liver cells in a mouse model of alcoholic steatohepatitis contain a miRNA signature detectable in the blood.READ MORE
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Comments | 0 ADD COMMENT
EMBL Course: Next Generation Sequencing: RNA Sequencing Library Preparation
Apr 23 - Apr 27, 2018
EMBO Practical Course: Microbial Metagenomics: A 360º Approach
Apr 23 - Apr 30, 2018
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018